A new platin compound, oxaliplatin, has significant activity in advanced co
lorectal carcinomas. However, its pharmacokinetics have not been characteri
zed adequately yet. This study extensively analyzes the pharmacokinetics of
both ultrafiltrable (free) and protein-bound platin in 13 patients receivi
ng 130 mg/m(2) oxaliplatin as a 4-h infusion in combination with 375 mg/m(2
) 5-fluorouracil as a 24-h infusion for advanced colorectal carcinomas. The
interpatient variability was very low for all parameters analyzed. The lev
els of free platin decreased triphasically, with a mean terminal half-life
of 27.3 +/- 10.6 h. The area under the time-concentration curve was 20.17 /- 6.97 mu g.h/ml and the total and renal clearances amounted to 222 +/- 65
and 121 +/- 56 ml/min, respectively. The values for the volume of distribu
tion and for the maximum concentration at the end of infusion were 349 +/-
132 liters and 1612 +/- 553 ng/ml, respectively. On the basis of the simula
tion of the plasma levels and the urinary excretion of platin following the
long-term administration of oxaliplatin as a constant-rate and a chronomod
ulated infusion, additional analyses are warranted to fully characterize th
e pharmacokinetics of the drug in these settings.